Mansoor R Mirza
NSGO-CTU · NSGO · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mansoor R Mirza as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:54 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05574673 · Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination PhenotypeNordic Society of Gynaecological Oncology - Clinical Trials Unit · recruiting · Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer · study chair
- Ph2NCT05201001 · APX005M in Patients With Recurrent Ovarian CancerNordic Society of Gynaecological Oncology - Clinical Trials Unit · withdrawn · Ovarian Cancer · study chair
- Ph2NCT03267589 · Trial in Patients With Relapsed Ovarian CancerNordic Society of Gynaecological Oncology - Clinical Trials Unit · completed · Ovarian Cancer · study director
- Ph2NCT02730429 · Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial CancerNordic Society of Gynaecological Oncology - Clinical Trials Unit · completed · Endometrial Cancer · study chair
- Ph2NCT02730416 · Combination Chemotherapy With Nintedanib / Placebo in Endometrial CancerNordic Society of Gynaecological Oncology - Clinical Trials Unit · completed · Endometrial Cancer · study chair
- Ph1/Ph2NCT02354131 · Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerNordic Society of Gynaecological Oncology - Clinical Trials Unit · completed · Ovarian Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:54 UTC. The ranking covers the 200 most relevant of 56 PubMed records, and a shared surname and initials can bring in a namesake. All 56 on PubMed
- 2,017 citationsRCR 64.0
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.N Engl J Med · 20191,854 citationsRCR 69.4
- A phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med · 20111,749 citationsRCR 45.0
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.J Clin Oncol · 20141,311 citationsRCR 39.3
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.N Engl J Med · 2023744 citationsRCR 66.0
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol · 2015683 citationsRCR 21.5
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.N Engl J Med · 2021283 citationsRCR 17.2
- Incorporation of pazopanib in maintenance therapy of ovarian cancer.J Clin Oncol · 2014250 citationsRCR 7.4
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.J Clin Oncol · 2016221 citationsRCR 5.9
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.Lancet Oncol · 2019216 citationsRCR 7.1